IN2014CN02315A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN02315A IN2014CN02315A IN2315CHN2014A IN2014CN02315A IN 2014CN02315 A IN2014CN02315 A IN 2014CN02315A IN 2315CHN2014 A IN2315CHN2014 A IN 2315CHN2014A IN 2014CN02315 A IN2014CN02315 A IN 2014CN02315A
- Authority
- IN
- India
- Prior art keywords
- proliferation
- formula
- carcinoma cells
- mucoepidermoid carcinoma
- imidazoquinolines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541758P | 2011-09-30 | 2011-09-30 | |
| US201261660377P | 2012-06-15 | 2012-06-15 | |
| PCT/US2012/057480 WO2013049300A1 (fr) | 2011-09-30 | 2012-09-27 | Procédé de traitement du carcinome mucoépidermoïde |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN02315A true IN2014CN02315A (fr) | 2015-06-19 |
Family
ID=47016842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2315CHN2014 IN2014CN02315A (fr) | 2011-09-30 | 2012-09-27 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140243396A1 (fr) |
| EP (1) | EP2760445A1 (fr) |
| JP (1) | JP2014532057A (fr) |
| KR (1) | KR20140069038A (fr) |
| CN (1) | CN103906515A (fr) |
| AU (1) | AU2012316020A1 (fr) |
| BR (1) | BR112014005730A2 (fr) |
| CA (1) | CA2848065A1 (fr) |
| EA (1) | EA201490725A1 (fr) |
| IN (1) | IN2014CN02315A (fr) |
| MX (1) | MX2014003873A (fr) |
| WO (1) | WO2013049300A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016185443A1 (fr) | 2015-05-20 | 2016-11-24 | Novartis Ag | Combinaison pharmaceutique d'évérolimus et de dactolisib |
| AU2017363970A1 (en) | 2016-11-23 | 2019-06-20 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
| US20200362303A1 (en) * | 2017-11-30 | 2020-11-19 | Kyoto University | Maintenance-and-amplification method and differentiation induction method for primordial germ cells/primordial germ cell-like cells |
| WO2019157516A1 (fr) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Polythérapies |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2604629A1 (fr) | 2005-04-11 | 2006-10-19 | The Trustees Of Columbia University In The City Of New York | Methodes permettant de traiter les troubles cognitifs moderes |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN101541793A (zh) * | 2006-11-20 | 2009-09-23 | 诺瓦提斯公司 | 2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型 |
| WO2009052467A1 (fr) * | 2007-10-19 | 2009-04-23 | Board Of Regents Of The University Of Texas System | Procédés d'identification d'une résistance à l'inhibiteur de pi-3 kinase |
| WO2009067397A2 (fr) * | 2007-11-19 | 2009-05-28 | Ore Pharmaceuticals Inc. | Traitement de tumeurs solides |
| WO2009155659A1 (fr) * | 2008-06-27 | 2009-12-30 | The University Of Queensland | Polythérapie |
| US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| WO2011133668A2 (fr) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Méthodes et compositions utilisées pour le traitement du cancer |
| WO2012068487A1 (fr) * | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Présélection de patients pour un traitement thérapeutique fondé sur un état hypoxique, avec des agents sensibles à l'oxygène |
-
2012
- 2012-09-27 KR KR1020147007973A patent/KR20140069038A/ko not_active Application Discontinuation
- 2012-09-27 IN IN2315CHN2014 patent/IN2014CN02315A/en unknown
- 2012-09-27 EA EA201490725A patent/EA201490725A1/ru unknown
- 2012-09-27 CN CN201280047473.6A patent/CN103906515A/zh active Pending
- 2012-09-27 JP JP2014533710A patent/JP2014532057A/ja not_active Ceased
- 2012-09-27 CA CA2848065A patent/CA2848065A1/fr not_active Abandoned
- 2012-09-27 AU AU2012316020A patent/AU2012316020A1/en not_active Abandoned
- 2012-09-27 MX MX2014003873A patent/MX2014003873A/es unknown
- 2012-09-27 US US14/347,961 patent/US20140243396A1/en not_active Abandoned
- 2012-09-27 EP EP12772178.5A patent/EP2760445A1/fr not_active Withdrawn
- 2012-09-27 BR BR112014005730A patent/BR112014005730A2/pt not_active IP Right Cessation
- 2012-09-27 WO PCT/US2012/057480 patent/WO2013049300A1/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20140243396A1 (en) | 2014-08-28 |
| BR112014005730A2 (pt) | 2017-03-28 |
| WO2013049300A1 (fr) | 2013-04-04 |
| CN103906515A (zh) | 2014-07-02 |
| KR20140069038A (ko) | 2014-06-09 |
| AU2012316020A1 (en) | 2013-05-09 |
| MX2014003873A (es) | 2014-05-28 |
| EA201490725A1 (ru) | 2014-11-28 |
| CA2848065A1 (fr) | 2013-04-04 |
| EP2760445A1 (fr) | 2014-08-06 |
| JP2014532057A (ja) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013009256A (es) | Metodo para inhibir las celulas tumorales hamartoma. | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| IN2015DN01156A (fr) | ||
| WO2014028600A3 (fr) | Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci | |
| MY185103A (en) | Bezylamine derivatives as inhibitors of plasma kallikrein | |
| MY191358A (en) | Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer | |
| IN2014MN01755A (fr) | ||
| NZ608116A (en) | Triazine-oxadiazoles | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| MX360634B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. | |
| MY183582A (en) | Deuterated cftr potentiators | |
| IN2014KN00769A (fr) | ||
| IN2014MN00988A (fr) | ||
| MX343706B (es) | Derivados heterocíclicos novedosos. | |
| NZ700283A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| IN2015DN01119A (fr) | ||
| MX348726B (es) | Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune. | |
| MX353762B (es) | Inhibicion de il17 e ifn-gamma para el tratamiento de inflamacion autoinmune. | |
| NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
| MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
| IN2015DN03854A (fr) | ||
| MX361458B (es) | Compuestos de pirimido-piridazinona y uso de los mismos. | |
| MX2013008340A (es) | Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer. | |
| MX2015008187A (es) | Inhibidores de alk deuterados. |